Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 762.74

+0.9%

12:54 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (1994)	12/22/2016 5:05:44 PM
From: Miljenko Zuanic	of 3559

This note: "One limitation of the study is that it didn’t nail down any new disease genes that could lead to drug targets. That’s because the gene-disabling variants were rare—often found in only one or two individuals—and it takes more to make a statistically significant connection with a disease risk. “Even with 50,000, the numbers are very, very small,” Roden says." (http://www.sciencemag.org/news/2016/12/analysis-more-50000-genomes-hints-new-disease-causing-genes) ..... contradict Yan (several times repeated) statements that they already did identified NEW rare mutation(s) as potential critical "disease" mutation. I do not know whom to believe, but sure they will not ring all bells just to promote RGC. Wouldn't they?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next